Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018

Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

The ONCOLOGY team invites you to attend a meet and greet event with our team and members of our expert Advisory Board at the 60th American Society of Hematology (ASH) 2018 meeting in San Diego, California. Appetizers and drinks will be served!

Meet the following hematology/oncology experts:

  • Julie M. Vose, MD, MBA, FACP, FASCO
  • John Sweetenham, MD, FRCP
  • Stephen T. Rosen, MD

Event Details

Date: Saturday, December 1, 2018

Time: 2:00 PM to 3:00 PM

Location: Booth #3011 in the San Diego Convention Center Exhibit Hall
 

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Molecular Diagnostics, PIPAC Appear 'Exciting' in GI Cancer Surgical Care
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Prospective Study May Clarify PTEG Benefits in Malignant Bowel Obstruction
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
PTEG Elicits Encouraging Technical Outcomes in Malignant Bowel Obstruction
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Metastases
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Related Content
patients on the trial expected acupuncture to reduce cancer-related symptoms like pain and fatigue (4.2 ± 0.8), allow them to cope with their cancer (3.9 ± 1.0), decrease emotional distress (3.9 ± 1.0), and prevent future health problems (3.3 ± 1.1).

Social Detriments of Health Determine Acupuncture Expectancy in Breast Cancer

Ariana Pelosci
April 11th 2025
Article

Race, education, and arm pain were found to influence acupuncture expectancy in patients who are survivors of breast cancer.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

Chemo Effects May Outweigh Obesity-Related GI Alterations in Breast Cancer

Roman Fabbricatore
April 11th 2025
Article

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Post AHSCT Palliative Care Survey Shows Patient Needs, Clinician Perceptions Differ

Post AHSCT Palliative Care Survey Shows Patient Needs, Clinician Perceptions Differ

Tim Cortese
April 11th 2025
Article

The Integrated Palliative Care Outcome Scale showed the potential to guide palliative care integration to better help patients and clinicians after AHSCT.

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

Reshma L. Mahtani, DO ;Diana Lüftner;Denise Wrobel;Dagmar Guth;Matthias Zaiss;Jürgen Terhaag;Mark-Oliver Zahn;Lidia Pervola-Griff;Andrea Distelrath;Rachel Würstlein;Jörg Thomalla;Klaus Apel;Natalija Deuerling;Timo Schinköthe;Corinne Vannier;Rupert Bartsch;Christian Jackisch;Volkmar Müller;Marcus Schmidt;Marija Balic;Gabriel Rinnerthaler;Urs Breitenstein;Khalil Zaman;Michael Schwitter;Nadia Harbeck, MD, PhD
April 10th 2025
Article